• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

NEDD4家族在乳腺癌中的作用及治疗潜力

Role and therapeutic potential of the NEDD4 family in breast cancer.

作者信息

Zhang Xiaoxiao, Li Sijie

机构信息

Department of Breast Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.

出版信息

Front Pharmacol. 2025 Jun 4;16:1587675. doi: 10.3389/fphar.2025.1587675. eCollection 2025.

DOI:10.3389/fphar.2025.1587675
PMID:40535763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12174103/
Abstract

The high incidence and mortality rates of breast cancer (BC) continue to pose a significant threat to patient survival and life expectancy. An increasing number of recent studies have demonstrated the crucial role of the ubiquitin-proteasome system (UPS) in cancer initiation and progression. Of particular significance is the aberrant expression of the NEDD4 family, which belongs to the HECT-type E3 ubiquitin ligases, in BC progression. This review synthesizes current knowledge about the interactions between the NEDD4 family and various tumor-related signaling pathways and their roles in BC biology, providing a theoretical foundation for exploring novel prognostic markers and treatment strategies.

摘要

乳腺癌(BC)的高发病率和死亡率继续对患者的生存和预期寿命构成重大威胁。最近越来越多的研究表明泛素-蛋白酶体系统(UPS)在癌症发生和发展中起关键作用。特别重要的是,属于HECT型E3泛素连接酶的NEDD4家族在BC进展中存在异常表达。本综述综合了有关NEDD4家族与各种肿瘤相关信号通路之间相互作用及其在BC生物学中的作用的现有知识,为探索新的预后标志物和治疗策略提供理论基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/b49eb43b5b2b/fphar-16-1587675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/a85a3436d3f6/fphar-16-1587675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/cbf2361a9885/fphar-16-1587675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/62e7c094690f/fphar-16-1587675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/b49eb43b5b2b/fphar-16-1587675-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/a85a3436d3f6/fphar-16-1587675-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/cbf2361a9885/fphar-16-1587675-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/62e7c094690f/fphar-16-1587675-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6386/12174103/b49eb43b5b2b/fphar-16-1587675-g004.jpg

相似文献

1
Role and therapeutic potential of the NEDD4 family in breast cancer.NEDD4家族在乳腺癌中的作用及治疗潜力
Front Pharmacol. 2025 Jun 4;16:1587675. doi: 10.3389/fphar.2025.1587675. eCollection 2025.
2
Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer.PROTAC 降解的细胞周期蛋白依赖性激酶在乳腺癌治疗中的研究进展
Breast Cancer (Dove Med Press). 2025 Jun 13;17:511-521. doi: 10.2147/BCTT.S527906. eCollection 2025.
3
Comprehensive analysis of the role of NEDD4 in pan-cancer and experimental verification of its role in KIRC progression.NEDD4在泛癌中的作用综合分析及其在肾透明细胞癌进展中作用的实验验证。
Discov Oncol. 2025 Jun 17;16(1):1130. doi: 10.1007/s12672-025-02945-x.
4
Molecular feature-based classification of retroperitoneal liposarcoma: a prospective cohort study.基于分子特征的腹膜后脂肪肉瘤分类:一项前瞻性队列研究。
Elife. 2025 May 23;14:RP100887. doi: 10.7554/eLife.100887.
5
Interventions for fertility preservation in women with cancer undergoing chemotherapy.对接受化疗的癌症女性进行生育力保存的干预措施。
Cochrane Database Syst Rev. 2025 Jun 19;6:CD012891. doi: 10.1002/14651858.CD012891.pub2.
6
[Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations].[分子标志物IDO1、DCLK1和FOXC1在三阴性乳腺癌中的预后价值:形态学与临床相关性]
Arkh Patol. 2025;87(3):88-96. doi: 10.17116/patol20258703188.
7
Primary Amine-Based Photoclick Chemistry: From Concept to Diverse Applications in Chemical Biology and Medicinal Chemistry.基于伯胺的光点击化学:从概念到化学生物学和药物化学中的多样应用
Acc Chem Res. 2025 Jun 18. doi: 10.1021/acs.accounts.5c00158.
8
An Occupational Science Contribution to Camouflaging Scholarship: Centering Intersectional Experiences of Occupational Disruptions.职业科学对伪装学术的贡献:以职业中断的交叉经历为中心
Autism Adulthood. 2025 May 28;7(3):238-248. doi: 10.1089/aut.2023.0070. eCollection 2025 Jun.
9
Incidence and Risk Factors of Interval and Screen-Detected Breast Cancer.间期和筛查发现的乳腺癌的发病率及危险因素
JAMA Oncol. 2025 May 1;11(5):519-527. doi: 10.1001/jamaoncol.2025.0167.
10
Use of β-adrenoreceptor drugs and Parkinson's disease incidence in women from the French E3N cohort study.来自法国E3N队列研究的女性中β-肾上腺素能受体药物的使用与帕金森病发病率
J Parkinsons Dis. 2025 Apr 29:1877718X251330993. doi: 10.1177/1877718X251330993.

本文引用的文献

1
Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.乳腺癌中的非编码RNA:诊断和治疗意义
Int J Mol Sci. 2024 Dec 26;26(1):127. doi: 10.3390/ijms26010127.
2
Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.维泊妥珠单抗在日本雌激素受体阳性晚期乳腺癌患者中的安全性和药代动力学:一项1期研究
Int J Clin Oncol. 2025 Jan;30(1):72-82. doi: 10.1007/s10147-024-02648-3. Epub 2024 Nov 20.
3
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.
VERITAC-2 研究:维泊妥珠单抗,一种 PROTAC ER 降解剂,与氟维司群治疗 ER+/HER2- 晚期乳腺癌的 III 期临床研究。
Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. Epub 2024 Jul 29.
4
PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer.PI3K PROTAC 克服了 PIK3CA 突变型 HER2 阳性乳腺癌对拉帕替尼的耐药性。
Cancer Lett. 2024 Aug 28;598:217112. doi: 10.1016/j.canlet.2024.217112. Epub 2024 Jul 8.
5
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets.肿瘤起始与早期癌变:分子机制与干预靶点。
Signal Transduct Target Ther. 2024 Jun 19;9(1):149. doi: 10.1038/s41392-024-01848-7.
6
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models.口服雌激素受体 PROTAC 降解剂(ARV-471)在 ER+ 乳腺癌模型中作为单药治疗以及与 CDK4/6 或 PI3K/mTOR 通路抑制剂联合使用具有高度疗效。
Clin Cancer Res. 2024 Aug 15;30(16):3549-3563. doi: 10.1158/1078-0432.CCR-23-3465.
7
TGF-β signaling in health, disease, and therapeutics.TGF-β 信号在健康、疾病和治疗中的作用。
Signal Transduct Target Ther. 2024 Mar 22;9(1):61. doi: 10.1038/s41392-024-01764-w.
8
Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.靶向双重降解 HER2 和 EGFR 可消除致癌信号,克服治疗耐药性,并抑制 HER2 阳性乳腺癌模型中的转移病灶。
Drug Resist Updat. 2024 May;74:101078. doi: 10.1016/j.drup.2024.101078. Epub 2024 Mar 13.
9
WW domains form a folded type of nuclear localization signal to guide YAP1 nuclear import.WW 结构域形成一种折叠型核定位信号,以指导 YAP1 的核输入。
J Cell Biol. 2024 Jun 3;223(6). doi: 10.1083/jcb.202308013. Epub 2024 Mar 15.
10
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.